IN192748B - - Google Patents

Info

Publication number
IN192748B
IN192748B IN778DE2000A IN192748B IN 192748 B IN192748 B IN 192748B IN 778DE2000 A IN778DE2000 A IN 778DE2000A IN 192748 B IN192748 B IN 192748B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Ashok Rampal
Rajeev Singh Ranhuvanshi
Manoj Kumar
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Priority to IN778DE2000 priority Critical patent/IN192748B/en
Priority to PCT/IB2001/001564 priority patent/WO2002017885A2/en
Priority to AU2001284324A priority patent/AU2001284324A1/en
Priority to EP01963298A priority patent/EP1315478A2/en
Priority to US09/941,970 priority patent/US20020081332A1/en
Publication of IN192748B publication Critical patent/IN192748B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN778DE2000 2000-08-29 2000-08-29 IN192748B (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
IN778DE2000 IN192748B (es) 2000-08-29 2000-08-29
PCT/IB2001/001564 WO2002017885A2 (en) 2000-08-29 2001-08-29 Controlled release formulation of erythromycin or a derivative thereof
AU2001284324A AU2001284324A1 (en) 2000-08-29 2001-08-29 Controlled release formulation of erythromycin or a derivative thereof
EP01963298A EP1315478A2 (en) 2000-08-29 2001-08-29 Controlled release formulation of erythromycin or a derivative thereof
US09/941,970 US20020081332A1 (en) 2000-08-29 2001-08-29 Controlled release formulation of erythromycin or a derivative thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN778DE2000 IN192748B (es) 2000-08-29 2000-08-29

Publications (1)

Publication Number Publication Date
IN192748B true IN192748B (es) 2004-05-15

Family

ID=11097084

Family Applications (1)

Application Number Title Priority Date Filing Date
IN778DE2000 IN192748B (es) 2000-08-29 2000-08-29

Country Status (5)

Country Link
US (1) US20020081332A1 (es)
EP (1) EP1315478A2 (es)
AU (1) AU2001284324A1 (es)
IN (1) IN192748B (es)
WO (1) WO2002017885A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
WO2001064224A1 (en) * 2000-02-29 2001-09-07 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
KR20030011797A (ko) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 맛이 차폐된 과립형 입자
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
WO2003017981A1 (en) * 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
CA2466808C (en) * 2001-11-21 2009-01-27 E-Z-Em, Inc. Formulations for use in medical or diagnostic procedures
BR0308990A (pt) * 2002-04-03 2005-01-04 Ranbaxy Lab Ltd Composição farmacêutica de eritromicina e seus derivados com sabor mascarado e processo de sua preparação
CA2481271A1 (en) * 2002-04-03 2003-10-09 Ranbaxy Laboratories Limited Clarithromycin formulations having improved bioavailability
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
WO2005004919A2 (en) * 2003-07-02 2005-01-20 Eurand, Inc. Extended release systems for macrolide antibiotics
CA2533165A1 (en) * 2003-07-21 2005-01-27 Bio-Dar Ltd. Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
AU2004258944B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2007502296A (ja) 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション ロバストペレット
US8062672B2 (en) 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005023184A2 (en) 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8168228B2 (en) 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US20050260263A1 (en) * 2004-05-18 2005-11-24 Panion & Bf Biotech Inc. Sustained release formulation for sparingly soluble main drugs
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2011125075A2 (en) * 2010-04-08 2011-10-13 Fdc Limited A novel gastroretentive delivery of macrolide
EP2671571A1 (en) * 2012-06-05 2013-12-11 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-release formulations of clarithromycin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4076804A (en) * 1975-07-18 1978-02-28 Abbott Laboratories Erythromycin therapy
GB1577196A (en) * 1977-06-03 1980-10-22 Ile De France Compositions containing erythromycin and metoclopramide
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
EE200100153A (et) * 1998-09-14 2002-06-17 Ranbaxy Laboratories Limited Kontrollitav ravimiväljutussüsteem ravimite suukaudseks manustamiseks, mis pakub ajalist ja ruumilist kontrolli
SI20150A (sl) * 1999-02-19 2000-08-31 Lek, Tovarna Farmacevtskih In Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina

Also Published As

Publication number Publication date
WO2002017885A3 (en) 2002-09-06
AU2001284324A1 (en) 2002-03-13
US20020081332A1 (en) 2002-06-27
EP1315478A2 (en) 2003-06-04
WO2002017885A2 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
BE2016C059I2 (es)
BE2014C019I2 (es)
BE2014C009I2 (es)
BE2013C048I2 (es)
BE2012C016I2 (es)
BE2010C019I2 (es)
JP2002544561A5 (es)
JP2003503118A5 (es)
BRPI0113085B8 (es)
JP2001274265A5 (es)
JP2002541912A5 (es)
BRPI0112928B8 (es)
BE2010C040I2 (es)
IN192748B (es)
JP2003501767A5 (es)
JP2001170797A5 (es)
JP2002026331A5 (es)
JP2000333451A5 (es)
BRPI0113372A8 (es)
JP2003513827A5 (es)
JP2002061023A5 (es)
JP2003516088A5 (es)
JP2001244823A5 (es)
JP2001213277A5 (es)
JP2001309393A5 (es)